The impact of hepatitis C virus infection on long-term outcome in renal transplant patients

Ruhı, Çağlar; Süleymanlar, İnci; Koçak, Hüseyin; Yılmaz, Vural Taner; Çolak, Dilek; Dınçkan, Ayhan; Gurkan, Alihan; Ersoy, Fevzi; Yakupoğlu, G; Süleymanlar, Gültekin

doi:10.4318/tjg.2011.0236

Cited by 7 publications

(6 citation statements)

References 26 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In isolation, HCVþ patients have significantly lower patient and graft survival compared with HCV seronegative transplant recipients both in our analysis and according to many other studies (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14). It has been suggested that the pattern of renal pathologic injury in HCVþ KTX patients derives from overlapping pathways: one mediated by HCV PCRþ infection itself and the other one related to enhanced cellular and humoral immune responses observed in the HCV-infected transplant population (24).…”

Section: Discussionsupporting

confidence: 75%

“…Despite a survival advantage over dialysis, reports of outcomes among kidney transplant recipients with HCVþ compared to those without hepatitis C virus (HCVÀ) are often conflicting. Whereas many studies have shown a detrimental effect of HCVþ on kidney transplant graft survival relative to HCVÀ recipients, others have not found a difference (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17). Interpretation of many of these reports is limited by various methodological issues.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of HCV, HIV and Coinfection in Kidney Transplant Recipients: Mate Kidney Analyses

Xia

Friedmann

Yaffe

et al. 2014

American Journal of Transplantation

View full text Add to dashboard Cite

Reports of kidney transplantation (KTX) in recipients with hepatitis C virus (HCVþ), human immunodeficiency virus (HIVþ) or coinfection often do not provide adequate adjustment for donor risk factors. We evaluated paired deceased-donor kidneys (derived from the same donor transplanted to different recipients) in which one kidney was transplanted into a patient with viral infection (HCVþ, n ¼ 1700; HIVþ, n ¼ 243) and the other transplanted into a recipient without infection (HCVÀ n ¼ 1700; HIVÀ n ¼ 243) using Scientific Registry of Transplant Recipients data between 2000 and 2013. On multivariable analysis (adjusted for recipient risk factors), HCVþ conferred increased risks of death-censored graft survival (DCGS) (adjusted hazard ratio [aHR] 1.24, 95% confidence interval [CI] 1.04-1.47) and patient survival (aHR 1.24, 95% CI 1.06-1.45) compared with HCVÀ. HIVþ conferred similar DCGS (aHR 0.85, 95% CI 0.48-1.51) and patient survival (aHR 0.80, 95% CI 0.39-1.64) compared with HIVÀ. HCV coinfection was a significant independent risk factor for DCGS (aHR 2.33; 95% CI 1.06, 5.12) and patient survival (aHR 2.88; 95% CI 1. 35, 6.12). On multivariable analysis, 1-year acute rejection was not associated with HCVþ, HIVþ or coinfection. Whereas KTX in HIVþ recipients were associated with similar outcomes relative to noninfected recipients, HCV monoinfection and, to a greater extent, coinfection were associated with poor patient and graft survival.

show abstract

Section: Discussionsupporting

confidence: 75%

Section: Introductionmentioning

confidence: 99%

Effect of HCV, HIV and Coinfection in Kidney Transplant Recipients: Mate Kidney Analyses

Xia

Friedmann

Yaffe

et al. 2014

American Journal of Transplantation

View full text Add to dashboard Cite

show abstract

“…In the present study, we found that HCV-positive patients remained for a longer period on RRT than HCV-negative patients, which is in line with earlier reports [32,42], but received transplants at a younger age than the control group, as in another study [43]. CsA was shown to inhibit HCV viral replication in cultured hepatocytes, and HCVpositive KT recipients treated with CsA showed stabilization and regression in liver fibrosis in >50% of the cases [22,23].…”

Section: Hepatitis C Virus Infection Is a Common And Important Diseassupporting

confidence: 94%

Lack of Impact of Hepatitis C Virus Infection on Graft Survival After Kidney Transplantation—A Portuguese Single-Center Experience

Magalhães-Costa

Lebre

Machado³

et al. 2015

Transplantation Proceedings

View full text Add to dashboard Cite

“…The authors concluded that, in HD patients, the presence of anti-HCV antibodies is an independent risk factor for death, because of increased risk of cirrhosis and hepatocellular carcinoma. Other research has shown that kidney transplantation (KT) improves the longterm survival of ESRD patients with HCV infection [19,20] . While there is considerable evidence that HCV infection threatens the success of KT, the survival of HCVinfected renal transplant recipients is better than that for HCV-infected HD patients who are on transplant waiting lists [21] .…”

Section: Impact Of Hcv On Survivalmentioning

confidence: 99%

Hepatitis C infection in hemodialysis patients: A review

Etık

Öcal

Boyacioglu

2015

WJH

View full text Add to dashboard Cite

Hepatitis C virus (HCV)-related liver disease is a significant cause of morbidity and mortality in patients with end-stage renal disease (ESRD) who is treated with dialysis or kidney transplantation (KT). The survival rate for HCV-infected renal transplant recipients is better than that for HCV-infected hemodialysis patients on transplant waiting lists. Early diagnosis and treatment HCV infection prior to KT prevents complications posttransplantation and reduces mortality. In addition to screening for anti-HCV antibodies and detecting HCV RNA, percutaneous liver biopsy is particularly valuable for assessing the stage of liver damage in HCV-infected patients, because the stage of fibrosis is important determining optimal treatment for HCV. Studies have been demonstrated that with conventional interferon (IFN) monotherapy or pegylated IFN monotherapy are similar efficacy and safety in HCV-infected hemodialysis patients. Sustained viral responses (SVRs) with these monotherapies have ranged approximately 30% to 40%. Limited reports support the use of IFN and ribavirin combination therapy as antiviral treatment for ESRD patients or patients on hemodialysis. Ribavirin can be started at low dose and careful monitoring for side effects. Patients that show SVR after treatment are strong candidates for KT. It is also generally accepted that ESRD patients with decompensated cirrhosis and portal hypertension should be referred to the liver transplant team for consideration of combined liver-KT.

show abstract

The impact of hepatitis C virus infection on long-term outcome in renal transplant patients

Cited by 7 publications

References 26 publications

Effect of HCV, HIV and Coinfection in Kidney Transplant Recipients: Mate Kidney Analyses

Effect of HCV, HIV and Coinfection in Kidney Transplant Recipients: Mate Kidney Analyses

Lack of Impact of Hepatitis C Virus Infection on Graft Survival After Kidney Transplantation—A Portuguese Single-Center Experience

Hepatitis C infection in hemodialysis patients: A review

Contact Info

Product

Resources

About